Interview with Rafael Martau, Commercial Director, Bomi Farma
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Address: R. Cônego Felipe, 365 – Taquara – Rio de Janeiro – RJ CEP: 22713-010,Brazil
Tel: (21) 2159-2600
Laboratórios Bagó do Brasil is a pharmaceutical company outlined by its competencies of innovation and vision of the future. The company is an important part of Bagó Group founded in 1934, in Argentina. Established in the country in 2002, its founders have created an organization with a solid reputation based on ethics and commitment to quality.
The slogan “Ethics at the service of Heath” holds an special place on guiding the company’s actions, and so does the premium, the priority ingredient of the organization’s roles.
With a head office and a plant in the city of Rio de Janeiro, a distribution center in Brasilia and representatives in the major centers of consumption in the country, the company develops, distributes and commercializes innovative pharmaceutical products.
With an excellence and reliability standing, the company progressively attracts more attention and the trustiness of the country’s medical class, acquiring the respect of Brazilian’s consumers.
Keflex
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two…
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could…
When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which…
In an exclusive interview, Otto Philipp Braun, part of medtech giant B. Braun’s family dynasty, discusses his achievements as MD in Brazil, the company’s operations in the country and globally, as…
When we met you in 2007, as the head of the former Igefarma, the company was undergoing a transition – from branded generics into dermocosmetics and women’s health. But since…
Rogerio, you were one of the people responsible for integrating two well-established companies in the Brazilian market with the acquisition of Exel by DHL in late 2005. How challenging was…
You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at…
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
See our Cookie Privacy Policy Here
